ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Forecast & Price Target
ArriVent BioPharma, Inc. Common Stock · NASDAQ
$29.99-0.17 (-0.56%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering ArriVent BioPharma, Inc. Common Stock, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $42.00 to $50.00, so the covering firms are broadly aligned. The average target of $44.83 sits 49% above the current $29.99. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 7 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-1.01 next quarter toward $-3.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to ArriVent BioPharma, Inc. Common Stock.
As of Jul, 7 of 7 firms rate AVBP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AVBP EPS & revenue forecast
EPS · NEXT QUARTER
$-1.01
Range $-1.26 – $-0.84 · 8 analysts · +21% YoY
Next period, 8 analysts expect ArriVent BioPharma, Inc. Common Stock to earn $-1.01 a share (range $-1.26 – $-0.84), versus $-0.83 a year earlier. Full-year consensus is $-4.09, growing to $-3.48 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $47.0M next year.
Top analysts covering ArriVent BioPharma, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AVBP.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$45.00+50.1% to target
Overall win rate
55%
+ Follow
#2
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$45.00+50.1% to target
Overall win rate
53%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$43.00+43.4% to target
Overall win rate
43%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$44.00+46.7% to target
Overall win rate
38%
+ Follow
#5
Jeff Jones
Oppenheimer · Rank #197
Buy
$50.00+66.7% to target
Overall win rate
34%
+ Follow
AVBP stock forecast FAQ
What is AVBP's average 12-month price target?+
The 6 analysts with a live target average $44.83 for ArriVent BioPharma, Inc. Common Stock over the next 12 months, ranging from a $50.00 high to a $42.00 low.
Is AVBP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AVBP?+
The Street-high target is $50.00 (Oppenheimer), and the Street-low is $42.00 (BTIG). The average of all 6 active targets is $44.83.
How many Wall Street analysts cover AVBP?+
7 analysts have an active rating on ArriVent BioPharma, Inc. Common Stock, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering AVBP?+
Among analysts who currently cover AVBP, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $45.00 target.
What is ArriVent BioPharma, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.01 per share (range $-1.26 – $-0.84) across 8 analysts. Full-year EPS is projected at $-4.09, rising to $-3.48 the following year.
How much revenue is ArriVent BioPharma, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $47.0M next year.
Have analysts been upgrading or downgrading AVBP lately?+
As of Jul, 7 of 7 firms rate AVBP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AVBP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
